Logo image
ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?
Editorial   Open access   Peer reviewed

ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Muhammad Muntazir Mehdi Khan and Casey J. Allen
Annals of surgical oncology
21 Apr 2026
PMID: 42012739
url
https://doi.org/10.1245/s10434-026-19700-3View
Published, Version of Record (VoR) Open Maybe Open Access (Publisher Bronze)

Abstract

Life Sciences & Biomedicine Science & Technology Oncology Surgery
Although the benefits of perioperative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) are well established, the role of adjuvant radiotherapy (adjXRT) following pancreaticoduodenectomy (PD) remains controversial. While the NCCN provides guidance regarding the use of adjXRT based on margin status, there is conflicting evidence supporting its role in nodal disease (N+) alone. [1st paragraph]

Metrics

2 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Surgery
Logo image